Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?

NCT ID NCT07723469

Not yet recruiting Disease control Sponsor: SURGE Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a single dose of SRG-514 (ketorolac), given directly into the area where a breast tumor is removed, can help prevent cancer from coming back. The study enrolls adults with stage II-III triple-negative breast cancer who are having breast-conserving surgery and have not had prior chemotherapy. Half receive standard care plus the drug; half receive standard care alone. Researchers will track how long participants remain cancer-free and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a single dose of the drug SRG-514 (ketorolac) injected into the tumor removal site during breast-conserving surgery
What this could lead to
If effective, this simple, one-time treatment during surgery could lower the risk of cancer returning in people with triple-negative breast cancer.
What could go wrong
This is an early-phase 3 trial, so the drug may not improve outcomes. Ketorolac is a common anti-inflammatory, but giving it directly into the surgical site carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke Cancer Center

    Durham, North Carolina, 27710, United States

    Contact Email: •••••@•••••

  • Mayo

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

  • NYU Langone Health

    New York, New York, 10016, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.